Page 1 | Search Results | Blood | American Society of Hematology

1-7 of 7

Sort by

Sort Order Select

Journal Articles

Sequential multiagent chemotherapy is not superior to high-dose cytarabine alone as postremission intensification therapy for acute myeloid leukemia in adults under 60 years of age: Cancer and Leukemia Group B Study 9222

Joseph O. Moore, Stephen L. George, Richard K. Dodge, Philip C. Amrein, Bayard L. Powell, Jonathan E. Kolitz, Maria R. Baer, Frederick R. Davey, Clara D. Bloomfield, Richard A. Larson, Charles A. Schiffer

Blood (2005) 105 (9): 3420–3427.

https://doi.org/10.1182/blood-2004-08-2977

Published: 2005

Journal Articles

Differences in prognostic factors and outcomes in African Americans and whites with acute myeloid leukemia

Mikkael A. Sekeres, Bercedis Peterson, Richard K. Dodge, Robert J. Mayer, Joseph O. Moore, Edward J. Lee, Jonathan Kolitz, Maria R. Baer, Charles A. Schiffer, Andrew J. Carroll, James W. Vardiman, Frederick R. Davey, Clara D. Bloomfield, Richard A. Larson, Richard M. Stone, for the Cancer and Leukemia Group B (CALGB)

Blood (2004) 103 (11): 4036–4042.

https://doi.org/10.1182/blood-2003-09-3118

Published: 2004

Journal Articles

Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461): Presented in part at the 43rd annual meeting of the American Society of Hematology, Orlando, FL, December 10, 2001, and published in abstract form. 59

John C. Byrd, Krzysztof Mrózek, Richard K. Dodge, Andrew J. Carroll, Colin G. Edwards, Diane C. Arthur, Mark J. Pettenati, Shivanand R. Patil, Kathleen W. Rao, Michael S. Watson, Prasad R. K. Koduru, Joseph O. Moore, Richard M. Stone, Robert J. Mayer, Eric J. Feldman, Frederick R. Davey, Charles A. Schiffer, Richard A. Larson, Clara D. Bloomfield

Blood (2002) 100 (13): 4325–4336.

https://doi.org/10.1182/blood-2002-03-0772

Published: 2002

Journal Articles

High frequency of immunophenotype changes in acute myeloid leukemia at relapse: implications for residual disease detection (Cancer and Leukemia Group B Study 8361)

Maria R. Baer, Carleton C. Stewart, Richard K. Dodge, Gail Leget, Norbert Sulé, Krzysztof Mrózek, Charles A. Schiffer, Bayard L. Powell, Jonathan E. Kolitz, Joseph O. Moore, Richard M. Stone, Frederick R. Davey, Andrew J. Carroll, Richard A. Larson, Clara D. Bloomfield

Blood (2001) 97 (11): 3574–3580.

https://doi.org/10.1182/blood.V97.11.3574

Published: 2001

Journal Articles

Value of Immunophenotype in Intensively Treated Adult Acute Lymphoblastic Leukemia: Cancer and Leukemia Group B Study 8364

Myron S. Czuczman, Richard K. Dodge, Carleton C. Stewart, Stanley R. Frankel, Frederick R. Davey, Bayard L. Powell, Ted P. Szatrowski, Charles A. Schiffer, Richard A. Larson, Clara D. Bloomfield

Blood (1999) 93 (11): 3931–3939.

https://doi.org/10.1182/blood.V93.11.3931

Published: 1999

Journal Articles

A Randomized Controlled Trial of Filgrastim During Remission Induction and Consolidation Chemotherapy for Adults With Acute Lymphoblastic Leukemia: CALGB Study 9111

Richard A. Larson, Richard K. Dodge, Charles A. Linker, Richard M. Stone, Bayard L. Powell, Edward J. Lee, Philip Schulman, Frederick R. Davey, Stanley R. Frankel, Clara D. Bloomfield, Stephen L. George, Charles A. Schiffer

Blood (1998) 92 (5): 1556–1564.

https://doi.org/10.1182/blood.V92.5.1556

Published: 1998

Journal Articles

Expression of the Neural Cell Adhesion Molecule CD56 Is Associated With Short Remission Duration and Survival in Acute Myeloid Leukemia With t(8; 21)(q22; q22)

Maria R. Baer, Carleton C. Stewart, David Lawrence, Diane C. Arthur, John C. Byrd, Frederick R. Davey, Charles A. Schiffer, Clara D. Bloomfield

Blood (1997) 90 (4): 1643–1648.

https://doi.org/10.1182/blood.V90.4.1643

Published: 1997

NARROW

Sequential multiagent chemotherapy is not superior to high-dose cytarabine alone as postremission intensification therapy for acute myeloid leukemia in adults under 60 years of age: Cancer and Leukemia Group B Study 9222

Differences in prognostic factors and outcomes in African Americans and whites with acute myeloid leukemia

High frequency of immunophenotype changes in acute myeloid leukemia at relapse: implications for residual disease detection (Cancer and Leukemia Group B Study 8361)

Value of Immunophenotype in Intensively Treated Adult Acute Lymphoblastic Leukemia: Cancer and Leukemia Group B Study 8364

A Randomized Controlled Trial of Filgrastim During Remission Induction and Consolidation Chemotherapy for Adults With Acute Lymphoblastic Leukemia: CALGB Study 9111

Expression of the Neural Cell Adhesion Molecule CD56 Is Associated With Short Remission Duration and Survival in Acute Myeloid Leukemia With t(8; 21)(q22; q22)

Email alerts

ASH Publications

American Society of Hematology

Sequential multiagent chemotherapy is not superior to high-dose cytarabine alone as postremission intensification therapy for acute myeloid leukemia in adults under 60 years of age: Cancer and Leukemia Group B Study 9222

Differences in prognostic factors and outcomes in African Americans and whites with acute myeloid leukemia

High frequency of immunophenotype changes in acute myeloid leukemia at relapse: implications for residual disease detection (Cancer and Leukemia Group B Study 8361)

Value of Immunophenotype in Intensively Treated Adult Acute Lymphoblastic Leukemia: Cancer and Leukemia Group B Study 8364

A Randomized Controlled Trial of Filgrastim During Remission Induction and Consolidation Chemotherapy for Adults With Acute Lymphoblastic Leukemia: CALGB Study 9111

Expression of the Neural Cell Adhesion Molecule CD56 Is Associated With Short Remission Duration and Survival in Acute Myeloid Leukemia With t(8; 21)(q22; q22)

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only